Abstract
Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of anti-myeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine Nucleotides / administration & dosage*
-
Adenine Nucleotides / adverse effects*
-
Adult
-
Aged
-
Arabinonucleosides / administration & dosage*
-
Arabinonucleosides / adverse effects*
-
Clofarabine
-
Female
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / blood
-
Multiple Myeloma / drug therapy*
-
Neoplasm Recurrence, Local / blood
-
Neoplasm Recurrence, Local / drug therapy*
-
Neutropenia / blood
-
Neutropenia / chemically induced
Substances
-
Adenine Nucleotides
-
Arabinonucleosides
-
Clofarabine